NasdaqGS:REGNBiotechs
Regeneron (REGN) Stock Price Faces Margin Squeeze Despite 17% Revenue Growth
Regeneron Pharmaceuticals stock jumped about 3% to around US$763 after its latest report, a clear sign traders liked what they saw in the headline numbers. The bigger story sits in the profit engine behind that move. Quarterly basic earnings per share came in at US$12.62 on revenue of US$4.29b, while trailing net margin stands at 27.9%, compared with 31.4% a year earlier. In the short term, the market is cheering the earnings print. Over a longer horizon, investors now have to weigh that...